This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Philip M. Catalano, MD; Harvey Blank, MD
1416 59th St W Bradenton, FL 33529

Arch Dermatol. 1985;121(11):1381.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

An article entitled "Interaction Between Oral Contraceptives and Griseofulvin" appeared in the British Medical Journal in 1984.¹ This article suggested that systemic administration of griseofulvin in 22 women may have increased the metabolism, or, at any rate, decreased the effectiveness of the estrogen that was being used as part of a contraceptive pill. As a result, 15 patients experienced transient intermenstrual bleeding and five had amenorrhea; unintended pregnancies were reported in two other patients. In four women, two with intermenstrual bleeding and two with amenorrhea, a second exposure to griseofulvin resulted in recurrence of the original reaction. The authors did not state the formulation of griseofulvin (ie, ultramicrofine, microcrystalline, and so on) employed.

Of the two women with unintended pregnancy, one had used high-dose oral contraception for 15 months and had been receiving 500 mg/day of griseofulvin for 2 months. She also received co-trimoxazole for one . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?